Suraksha Diagnostic Ltd
Suraksha Diagnostic Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
FY26 revenue grew 23.1% YoY to INR3,104.1 million, with a three-year CAGR of 17.78% indicating strong structural growth. Revenue growth guidance for FY27 and beyond is around 15%, despite a 23% growth in FY26, with the company preferring cautious estimates and aiming to potentially over-deliver.
From Suraksha Diagnostic Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- FY26 revenue grew 23.1% YoY to INR3,104.1 million, with a three-year CAGR of 17.78% indicating strong structural growth.
- FY27 revenue growth guidance is around 15%, with management open to over-delivering but committing to a conservative 15%.
- Growth drivers include:
- Expansion: Adding multiple new hubs and spoke centers targeting West Bengal, Bihar, Jharkhand, and Tripura, increasing network size from 68 centers in FY26 to 82+ in FY27.
- New centers expected to contribute majority of growth; mature centers to contribute ~9% growth.
- Focus on ramping up throughput and capacity utilization in recently launched centers.
- Increasing share of specialized diagnostics and premium test mix, including genomics and advanced radiology.
2 more points from Suraksha Diagnostic Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Suraksha Diagnostic Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Planned capex for FY27 is around INR 70 crores.
- Capex includes opening five new hub centers and eight asset-light spoke centers.
- Expansion targets West Bengal, Bihar, Jharkhand, and Tripura.
- Two centers planned for last year had delayed openings; capex for those is nearly incurred.
- The company is focused on building specialized hubs and scaling diagnostics like genomics and advanced imaging.
2 more points from Suraksha Diagnostic Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Suraksha Diagnostic Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Suraksha Diagnostic Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Suraksha Diagnostic Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹81 Cr, net profit ₹6 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Suraksha Diagnostic Ltd's management said in earlier quarters
Others in Healthcare Services this season
- Suven Life Scie. (Q4 FY26)
The provided pages of the investor presentation do not report any revenue, sales, or volume figures for the quarter. Key investor presentation takeaways from Su
- Invicta Diagnostic Ltd (Q4 FY26)
Invicta Diagnostic Limited is deploying IPO funds (INR 21 crores raised) primarily towards: . Key concall takeaways from Invicta Diagnos.'s Q4 FY26 earnings…
- Star Imaging (Q4 FY26)
Capex planned for FY27 is around INR 20 to 25 crores, mainly towards new centres and equipment. Key concall takeaways from Star Imaging's Q4 FY26 earnings call…
- Gaudium IVF and Women Health Ltd (Q4 FY26)
Revenue growth seen in FY26: INR 104.35 crore, a 47.56% increase from FY25. Key concall takeaways from Gaudium IVF's Q4 FY26 earnings call — and how it ranks…
Arthneeti Pro · Annual
Suraksha Diagnostic Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Suraksha Diagnostic Ltd Q4 FY26 results?
FY26 revenue grew 23.1% YoY to INR3,104.1 million, with a three-year CAGR of 17.78% indicating strong structural growth. Revenue growth guidance for FY27 and beyond is around 15%, despite a 23% growth in FY26, with the company preferring cautious estimates and aiming to potentially over-deliver.
What is Suraksha Diagnostic Ltd share price analysis?
Suraksha Diagnostic Ltd currently shows a neutral. The stock trades at a P/E of 44.4 with a market cap of ₹1,588 Cr. Investors should review the full earnings analysis for detailed insights.
Is Suraksha Diagnostic Ltd planning capital expenditure?
Planned capex for FY27 is around INR 70 crores.
Keep Suraksha Diagnostic Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.